White Papers, Case Studies, Reports

Medable’s Patient Caregiver Network improves post-seizure trial data

A pharmaceutical contract research organization (CRO) expressed concerns about the timing and availability of seizure diaries for patients enrolled in their rare disease study. 

They wanted to understand when patients should be prompted to complete the diaries and how they could improve the process to better accommodate caregivers' and patients' needs to  produce better trial data.

White Papers, Case Studies, Reports

Medable platform speeds diabetes study startup by 50%

eCOA
6 min

A top 10 pharmaceutical company approached Medable seeking support for their PhaseIII diabetes study in the highly competitive weight loss market. Their primary goal was toreduce the client’s average study build timelines from 16-20 weeks, down to just 8 weeks,a reduction of more than 50%.

See how Medable was able to meet the customer's goal with this case study.

White Papers, Case Studies, Reports

Record-breaking enrollment achieved in weight-loss study

A top 10 pharmaceutical company approached Medable seeking support for their Phase III diabetes study. Their primary goal was to reduce the participant enrollment phase timeline to get the study underway as quickly as possible.

White Papers, Case Studies, Reports

ePROs: Transforming oncology trial research

ePRO
6 min

Over the last decade the number of oncology trials has skyrocketed, almost doubling the number of all other therapeutic areas combined, according to the WIRB-Copernicus Group¹. Known for their complex design, oncology trials often present various participant, site, and sponsor hurdles.

Sponsors and CROs looking to tackle these challenges andreduce the burden on participants and sites should explore the potential of digital solutions, particularly electronic informed consent (eConsent) and electronic patient reported outcomes (ePRO). Both tools offer expanded views of the participant journey while offering feedback that enables sponsors and CROs to enhance and refine their trials for all stakeholders.

White Papers, Case Studies, Reports

The Digital Future is Now eBook

DCT
6 min

According to Grandview Research,the hybrid and decentralized clinicaltrial (DCT) market will be worth more than 12 billion dollars by 2030. Sparked by the COVID-19 pandemic of 2020, the rapid ascent of patient centered technology and the digital and decentralized trials they’ve spawned has forever changed the landscape of clinical conduct.

White Papers, Case Studies, Reports

The Definitive Guide to Digital Evidence Generation

According to Grandview Research, the hybrid and decentralized clinical trial (DCT) market will be worth more than 12 billion dollars by 2030. Sparked by the COVID-19 pandemic of 2020, the rapid ascent of patient-centered technology and the digital and decentralized trials they’ve spawned has forever changed the landscape of clinical conduct. Sponsors are increasingly turning to DCT platforms in alignment with the rise of Life Science and Software-as-a-Service (SaaS) solutions. For those who haven't made the jump yet, there are many questions, including "What is a decentralized clinical trial?" Find out with this in-depth guide to decentralized clinical trials. Uncover how they work, their benefits, and how they transform clinical development.

PI on tablet
White Papers, Case Studies, Reports

Use case: Implementing digital solutions to improve oncology trial experience & efficiency

A top 10 pharmaceutical company looked to Medable to streamline participant burden and enhance site and team experience in oncology trials, while establishing a scalable template for future trials in oncology and other areas.

White Papers, Case Studies, Reports

Report: Medable named #1 Leader in DCT for second year by Everest Group

For the second consecutive year, Medable has been named Leader decentralized clinical trial products per the Everest Group’s PEAK Matrix® assessment, which evaluates DCT products from 24 companies based on vision, capability and market impact.

woman on televisit
White Papers, Case Studies, Reports

ePRO Case study: Better options and outcomes oncology trials.

ePRO
6 min

Medable worked with a top 5 pharma company to increase the safety of patients as anti-cancer treatments may cause pulmonary toxicity, ranging from asymptomatic radiological changes to respiratory failure, and is considered a common side effect.

White Papers, Case Studies, Reports

Tufts CSDD Impact report: Decentralized and hybrid trials deliver greater ROI than traditional trials

The Tufts Center for the Study of Drug Development completed an analysis of its financial modeling study of decentralized clinical trials  using real data from Medable-enabled studies. These findings net financial benefits ranging from 5x for Phase II and 13x for Phase III trials, equating to roughly $10 million ROI and $39 million ROI, respectively.

White Papers, Case Studies, Reports

White paper: Why eConsent primes patients and studies for success

Read this white paper to learn how eConsent's flexibility helps you educate and retain patients worldwide, regardless of signature requirements, and how to implement it across your organization.

White Papers, Case Studies, Reports

White paper: Tips for tailoring eConsent for optimal patient centricity.

Use a consent experience that’s designed to meet the needs of patients, while educating and engaging them each step of the way. Read our free white paper to learn eConsent tips from patients themselves, and improve your patient retention.

See how Medable can make your trials more efficient.